Provided herein are compounds of the formula (I):
as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of metabolic diseases and disorders such as, for example, type II diabetes mellitus.
The invention relates to substituted carbo- and heterocyclic spiro compounds of the formula Ia which inhibit thiol proteases, to processes for their preparation and to the use thereof as medicaments.
[EN] NOVEL KETO-OXADIAZOLE DERIVATIVES AS CATHEPSIN INHIBITORS<br/>[FR] NOUVEAUX DERIVES DE CETO-OXADIAZOLE COMME INHIBITEURS DE LA CATHEPSINE
申请人:AVENTIS PHARMA INC
公开号:WO2005040142A1
公开(公告)日:2005-05-06
Novel difluorinated amide derivatives of Formula (II) as inhibitors of cathepsin S, K, B, and L, the pharmaceutically acceptable salts and N-oxides thereof, their uses as therapeutic agents and the methods of their making.
Formula (II)的新颖二氟化酰胺衍生物作为猫hepsin S、K、B和L的抑制剂,其药用盐和N-氧化物,它们作为治疗剂的用途以及其制备方法。
[EN] PYRROLIDINONE GLUCOKINASE ACTIVATORS<br/>[FR] ACTIVATEURS DE PYRROLIDINONE GLUCOKINASE
申请人:HOFFMANN LA ROCHE
公开号:WO2009127546A1
公开(公告)日:2009-10-22
Provided herein are compounds of the formula (I): wherein X, R1, R2 and R3 are as defined in the specification, as well as pharmaceutically acceptable salts thereof. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of metabolic diseases and disorders such as, for example, type II diabetes mellitus.
Novel compounds and compositions as cathepsin inhibitors
申请人:Thurairatnam Sukanthini
公开号:US20060189657A1
公开(公告)日:2006-08-24
Novel inhibitors of cathepsin S, K, B, and L, the pharmaceutically acceptable salts and N-oxides thereof, their uses as therapeutic agents and the methods of their making.